|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2007-4-3
|
|
pubmed:abstractText |
Advanced ovarian cancers are initially responsive to combinatorial chemotherapy with platinum drugs and taxanes but, in most cases, develop drug resistance. We recently showed that, in vitro, hepatocyte growth factor (HGF) enhances death of human ovarian cancer cell lines treated with cisplatin (CDDP) and paclitaxel. The present study addresses whether in vivo HGF makes ovarian carcinoma cells more responsive to these chemotherapeutics.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2191-8
|
|
pubmed:meshHeading |
pubmed-meshheading:17404103-Animals,
pubmed-meshheading:17404103-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17404103-Apoptosis,
pubmed-meshheading:17404103-Blotting, Western,
pubmed-meshheading:17404103-Cell Line, Tumor,
pubmed-meshheading:17404103-Cisplatin,
pubmed-meshheading:17404103-Drug Resistance, Neoplasm,
pubmed-meshheading:17404103-Female,
pubmed-meshheading:17404103-Flow Cytometry,
pubmed-meshheading:17404103-Gene Therapy,
pubmed-meshheading:17404103-Genetic Vectors,
pubmed-meshheading:17404103-Hepatocyte Growth Factor,
pubmed-meshheading:17404103-Humans,
pubmed-meshheading:17404103-Lentivirus,
pubmed-meshheading:17404103-Mice,
pubmed-meshheading:17404103-Ovarian Neoplasms,
pubmed-meshheading:17404103-Paclitaxel,
pubmed-meshheading:17404103-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:17404103-Transgenes
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo.
|
|
pubmed:affiliation |
Laboratory of Cancer Genetics and Division of Molecular Oncology of the Institute for Cancer Research and Treatment, University of Torino School of Medicine, Candiolo, Turin, Italy.
|
|
pubmed:publicationType |
Journal Article,
In Vitro,
Research Support, Non-U.S. Gov't
|
